Boston Scientific Corp. projects third quarter sales between $1.97 billion and $2.04 billion and net income of between $90 million and $145 million, according to preliminary results posted today.
The Natick-based medical device maker also says it will post a third quarter charge $70 million, or $0.05 per share, related to its acquisition of Guidant Corp.
Sales of the company’s stent system, used to prop open damaged blood vessels, are estimated at between $550 million and $580 million with roughly $375 million coming from the U.S. market.
The company projects earnings per share between $0.01 to $0.05.
Related:
